The Experts below are selected from a list of 203883 Experts worldwide ranked by ideXlab platform
Heming Wang - One of the best experts on this subject based on the ideXlab platform.
-
genome wide association analysis of self reported Daytime sleepiness identifies 42 loci that suggest biological subtypes
Nature Communications, 2019Co-Authors: Heming Wang, Jacqueline M Lane, Samuel E Jones, Hassan S Dashti, Hanna Ollila, Andrew R Wood, V Van HeesAbstract:Excessive Daytime sleepiness (EDS) affects 10–20% of the population and is associated with substantial functional deficits. Here, we identify 42 loci for self-reported Daytime sleepiness in GWAS of 452,071 individuals from the UK Biobank, with enrichment for genes expressed in brain tissues and in neuronal transmission pathways. We confirm the aggregate effect of a genetic risk score of 42 SNPs on Daytime sleepiness in independent Scandinavian cohorts and on other sleep disorders (restless legs syndrome, insomnia) and sleep traits (duration, chronotype, accelerometer-derived sleep efficiency and Daytime naps or inactivity). However, individual Daytime sleepiness signals vary in their associations with objective short vs long sleep, and with markers of sleep continuity. The 42 sleepiness variants primarily cluster into two predominant composite biological subtypes - sleep propensity and sleep fragmentation. Shared genetic links are also seen with obesity, coronary heart disease, psychiatric diseases, cognitive traits and reproductive ageing. A main symptom of chronic insufficient sleep is excessive Daytime sleepiness. Here, Wang et al. report 42 genome-wide significant loci for self-reported Daytime sleepiness in 452,071 individuals from the UK Biobank that cluster into two biological subtypes of either sleep propensity or sleep fragmentation.
-
genome wide association analysis of self reported Daytime sleepiness identifies 42 loci that suggest biological subtypes
Nature Communications, 2019Co-Authors: Heming Wang, Jacqueline M Lane, Samuel E Jones, Hassan S Dashti, Hanna Ollila, Andrew R Wood, Vincent T Van HeesAbstract:Excessive Daytime sleepiness (EDS) affects 10-20% of the population and is associated with substantial functional deficits. Here, we identify 42 loci for self-reported Daytime sleepiness in GWAS of 452,071 individuals from the UK Biobank, with enrichment for genes expressed in brain tissues and in neuronal transmission pathways. We confirm the aggregate effect of a genetic risk score of 42 SNPs on Daytime sleepiness in independent Scandinavian cohorts and on other sleep disorders (restless legs syndrome, insomnia) and sleep traits (duration, chronotype, accelerometer-derived sleep efficiency and Daytime naps or inactivity). However, individual Daytime sleepiness signals vary in their associations with objective short vs long sleep, and with markers of sleep continuity. The 42 sleepiness variants primarily cluster into two predominant composite biological subtypes - sleep propensity and sleep fragmentation. Shared genetic links are also seen with obesity, coronary heart disease, psychiatric diseases, cognitive traits and reproductive ageing.
Timothy J Craig - One of the best experts on this subject based on the ideXlab platform.
-
the role of montelukast on perennial allergic rhinitis and associated sleep disturbances and Daytime somnolence
Allergy and Asthma Proceedings, 2008Co-Authors: Carah B Santos, Christopher Hanks, Jeffrey Mccann, E L Pratt, Erik Lehman, Timothy J CraigAbstract:: Perennial allergic rhinitis (PAR) often causes sleep disturbances and associated Daytime somnolence, thus resulting in a poor quality of life. Various clinical interventions in patients suffering from the disorder seek to improve symptoms and quality of life. Additional studies are needed to establish whether the alleviation of PAR symptoms, particularly the reduction of congestion, will improve sleep quality and reduce Daytime somnolence. This study seeks to determine whether treatment with montelukast is more effective than placebo in reducing nasal congestion and sleep disturbances, resulting in reduced Daytime somnolence and fatigue in patients with PAR. Thirty-one subjects were enrolled in a double-blinded, placebo-controlled study using Balaam's design. Patients were treated with montelukast or placebo. Collected subjective data included a daily diary recording nasal symptoms, sleep issues, and Daytime fatigue, the Functional Outcomes of Sleep Questionnaire, the Epworth Sleepiness Scale, Juniper's Rhinoconjunctivitis Quality of Life Questionnaire, the Rhinitis Severity Scale, the Calgary Sleep Apnea Quality of Life Index, and Trail Making tests. Subjects treated with montelukast, compared with placebo, showed a statistically significant improvement in Daytime somnolence (p = 0.0089) and Daytime fatigue (p = 0.0087), with both factors improving with montelukast and worsening with placebo. In a small cohort of subjects, montelukast, when compared with placebo, improved the symptoms of PAR and reduced the fatigue and Daytime somnolence associated with the disorder.
-
the effect of intranasal steroid budesonide on the congestion related sleep disturbance and Daytime somnolence in patients with perennial allergic rhinitis
Allergy and Asthma Proceedings, 2005Co-Authors: F Gurevich, Casey Glass, Jeffery Mccann, L H Fisher, Salman Chegini, Cathy Mende, Michael J. Davies, Timothy J CraigAbstract:Abstract Patients with perennial allergic rhinitis (PAR) often present with nasal congestion, poor sleep, Daytime fatigue, and Daytime somnolence. Pharmacologic therapy that reduces nasal congestion should improve the PAR patients' sleep quality and reduce Daytime somnolence and fatigue. Our hypothesis is that intranasal steroid budesonide (BUD), an effective topical anti-inflammatory agent, will reduce nasal congestion and improve the patients' quality of life. The objective of this study was to determine whether topical steroid BUD improves sleep, Daytime somnolence, and fatigue in patients with PAR. Twenty-six subjects were enrolled in a double-blind, placebo-controlled, crossover study using Balaam's design. Patients were treated with intranasal steroid spray BUD or placebo. The Epworth Sleepiness Scale, daily diary, and questionnaires were used as tools for subjective data analysis, which focused on nasal symptoms, sleep quality, Daytime somnolence, and fatigue. The results were summarized and compared by PROC MIXED in SAS. The daily diary data showed significant improvement in self-reported nasal congestion (p = 0.04) and Daytime sleepiness (p = 0.01) and a trend in reduction of Daytime fatigue (p = 0.08) in the BUD group compared with the placebo group. The sleep measures showed statistically significant improvement in total sleep measures score (p = 0.04), "sleep compared with absolute" (p = 0.01), and "refreshing and restorative" sleep (p = 0.04) in the active group. Nasal corticosteroid BUD is effective in reducing nasal congestion, Daytime somnolence, and Daytime fatigue, and improving sleep quality in PAR.
-
nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and Daytime fatigue and the response to topical nasal corticosteroids
The Journal of Allergy and Clinical Immunology, 1998Co-Authors: Timothy J Craig, Erik Lehman, S Teets, Vernon M Chinchilli, Clifford ZwillichAbstract:Abstract Background: Allergic rhinitis (AR) is a frequent disease affecting up to 20% of the population. AR causes a hypersensitivity reaction, which results in inflamed nasal mucosa and nasal congestion. Negative pressure generated during inspiration in the nasal airway secondary to nasal congestion may lead to nasal collapse, airway obstruction, and an increased number of sleep microarousals. Sleep disturbances and microarousals can detrimentally affect Daytime energy levels, mood, and Daytime function. It is unknown whether treatment directed to reduce congestion may reduce these microarousals, sleep problems, and, consequently, associated Daytime fatigue. Objective: We sought to determine whether reducing nasal congestion with nasal steroids will reduce sleep complaints and Daytime sleepiness. Method: We enrolled 20 subjects in a double-blind, placebo-controlled study using Balaam's Design. Patients were treated with topical nasal corticosteroids or placebo. Subjective data were collected by use of a daily diary, which focused on nasal symptoms, sleep, and Daytime sleepiness. Results: The results demonstrated that nasal congestion and subjective sleep improved significantly in the topical corticosteroid–treated subjects but not in the placebo group. Sleepiness improved, but not significantly ( p = 0.08). Conclusion: Often, people with perennial allergies may attribute their Daytime fatigue to causes such as the side effects of medications, when in fact, the fatigue may be a result of nasal congestion and associated sleep fragmentation. Decreasing nasal congestion with nasal steroids may improve sleep, Daytime fatigue, and the quality of life of patients with AR. (J Allergy Clin Immunol 1998;101:633-7.)
Takayuki Kuriyama - One of the best experts on this subject based on the ideXlab platform.
-
Daytime hypercapnia in obstructive sleep apnea syndrome.
Chest, 2007Co-Authors: Naoko Kawata, Koichiro Tatsumi, Jiro Terada, Yuji Tada, Nobuhiro Tanabe, Yuichi Takiguchi, Takayuki KuriyamaAbstract:Background The pathogenesis of Daytime hypercapnia (Pa co 2 ≥ 45 mm Hg) may be directly linked to the existence of obstructive sleep apnea syndrome (OSAS) per se , although only some patients with OSAS exhibit Daytime hypercapnia. Objective To investigate the prevalence of Daytime hypercapnia in patients with OSAS; the association of Daytime hypercapnia and obesity, obstructive airflow limitation, restrictive lung impairment, and severity of sleep apnea; and the response to continuous positive airway pressure (CPAP) therapy in a subset of subjects. Methods The study involved 1,227 patients with OSAS who visited a sleep clinic and were examined using polysomnography. As for the response to CPAP therapy, the patients were considered good responders if their Daytime Pa co 2 decreased ≥ 5 mm Hg and poor responders if it decreased Results Fourteen percent (168 of 1,227 patients) exhibited Daytime hypercapnia. These patients had significantly higher body mass index (BMI) and apnea-hypopnea index (AHI) values compared with normocapnic patients, while percentage of predicted vital capacity (%VC) and FEV 1 /FVC ratio did not differ between the two groups. Logistic regression analysis showed that only AHI was a predictor of Daytime hypercapnia (p Conclusion The pathogenesis of Daytime hypercapnia may be directly linked to sleep apnea in a subgroup of patients with OSAS.
-
Daytime Hypercapnia in Obstructive Sleep Apnea Syndrome. Commentary
Chest, 2007Co-Authors: Clifford W. Zwillich, Carolyn H. Welsh, Naoko Kawata, Koichiro Tatsumi, Jiro Terada, Yuji Tada, Nobuhiro Tanabe, Yuichi Takiguchi, Takayuki KuriyamaAbstract:Background: The pathogenesis of Daytime hypercapnia (Paco 2 ≥ 45 mm Hg) may be directly linked to the existence of obstructive sleep apnea syndrome (OSAS) per se, although only some patients with OSAS exhibit Daytime hypercapnia. Objective: To investigate the prevalence of Daytime hypercapnia in patients with OSAS; the association of Daytime hypercapnia and obesity, obstructive airflow limitation, restrictive lung impairment, and severity of sleep apnea; and the response to continuous positive airway pressure (CPAP) therapy in a subset of subjects. Methods: The study involved 1,227 patients with OSAS who visited a sleep clinic and were examined using polysomnography. As for the response to CPAP therapy, the patients were considered good responders if their Daytime Paco 2 decreased ≥ 5 mm Hg and poor responders if it decreased < 5 mm Hg. Results: Fourteen percent (168 of 1,227 patients) exhibited Daytime hypercapnia. These patients had significantly higher body mass index (BMI) and apnea-hypopnea index (AHI) values compared with normocapnic patients, while percentage of predicted vital capacity (%VC) and FEV 1 /FVC ratio did not differ between the two groups. Logistic regression analysis showed that only AHI was a predictor of Daytime hypercapnia (p < 0.0001), while BMI (p = 0.051) and %VC (p = 0.062) were borderline predictors of Daytime hypercapnia. Daytime hypercapnia was corrected in some patients (51%, 19 of 37 patients) with severe OSAS after 3 months of CPAP therapy. Conclusion: The pathogenesis of Daytime hypercapnia may be directly linked to sleep apnea in a subgroup of patients with OSAS. (CHEST 2007: 132: 1832 - 1838) subgroup of patients with OSAS.
-
Daytime Pulmonary Hypertension in the Obstructive Sleep Apnea Syndrome
Nihon Kyobu Shikkan Gakkai zasshi, 1995Co-Authors: Toshihide Shinozaki, Koichiro Tatsumi, Tetsuya Sakuma, Shigeru Masuyama, Kunihiko Kato, Osamu Okada, Hiroshi Kimura, Takayuki KuriyamaAbstract:Patients with obstructive sleep apnea syndrome (OSAS) may have Daytime pulmonary hypertension (PH). Transient and sometimes severe elevations of pulmonary arterial pressure during sleep as a result of intermittent upper airway obstruction may lead to Daytime PH. We sought to study the factors involved in the development of Daytime PH. Right-heart catheterization, pulmonary function tests, and arterial blood gas measurements were done in 25 patients in whom OSAS was diagnosed by whole-night polysomnography. Eight of the patients (32%) had PH, defined by a mean pulmonary arterial (PA) pressure > or = 20 mmHg. For the group as a whole, mean PA pressure was positively and significantly correlated with Daytime PaCO2 (r = 0.79), percent of ideal body weight (r = 0.45), and Hb (r = 0.40). Mean PA pressure was negatively and significantly correlated with PaO2 (r = -0.54), FEV 1% (r = -0.52), and %FVC (r = -0.68). In contrast, mean PA pressure was not significantly correlated with apnea index or with sleep desaturation. These data indicate that Daytime PH was not directly related to sleep-disordered breathing, but was related to Daytime hypoxemia, Daytime hypercapnia, obesity, obstructive and restrictive respiratory impairments, and secondary polycythemia.
Jacqueline M Lane - One of the best experts on this subject based on the ideXlab platform.
-
genome wide association analysis of self reported Daytime sleepiness identifies 42 loci that suggest biological subtypes
Nature Communications, 2019Co-Authors: Heming Wang, Jacqueline M Lane, Samuel E Jones, Hassan S Dashti, Hanna Ollila, Andrew R Wood, V Van HeesAbstract:Excessive Daytime sleepiness (EDS) affects 10–20% of the population and is associated with substantial functional deficits. Here, we identify 42 loci for self-reported Daytime sleepiness in GWAS of 452,071 individuals from the UK Biobank, with enrichment for genes expressed in brain tissues and in neuronal transmission pathways. We confirm the aggregate effect of a genetic risk score of 42 SNPs on Daytime sleepiness in independent Scandinavian cohorts and on other sleep disorders (restless legs syndrome, insomnia) and sleep traits (duration, chronotype, accelerometer-derived sleep efficiency and Daytime naps or inactivity). However, individual Daytime sleepiness signals vary in their associations with objective short vs long sleep, and with markers of sleep continuity. The 42 sleepiness variants primarily cluster into two predominant composite biological subtypes - sleep propensity and sleep fragmentation. Shared genetic links are also seen with obesity, coronary heart disease, psychiatric diseases, cognitive traits and reproductive ageing. A main symptom of chronic insufficient sleep is excessive Daytime sleepiness. Here, Wang et al. report 42 genome-wide significant loci for self-reported Daytime sleepiness in 452,071 individuals from the UK Biobank that cluster into two biological subtypes of either sleep propensity or sleep fragmentation.
-
genome wide association analysis of self reported Daytime sleepiness identifies 42 loci that suggest biological subtypes
Nature Communications, 2019Co-Authors: Heming Wang, Jacqueline M Lane, Samuel E Jones, Hassan S Dashti, Hanna Ollila, Andrew R Wood, Vincent T Van HeesAbstract:Excessive Daytime sleepiness (EDS) affects 10-20% of the population and is associated with substantial functional deficits. Here, we identify 42 loci for self-reported Daytime sleepiness in GWAS of 452,071 individuals from the UK Biobank, with enrichment for genes expressed in brain tissues and in neuronal transmission pathways. We confirm the aggregate effect of a genetic risk score of 42 SNPs on Daytime sleepiness in independent Scandinavian cohorts and on other sleep disorders (restless legs syndrome, insomnia) and sleep traits (duration, chronotype, accelerometer-derived sleep efficiency and Daytime naps or inactivity). However, individual Daytime sleepiness signals vary in their associations with objective short vs long sleep, and with markers of sleep continuity. The 42 sleepiness variants primarily cluster into two predominant composite biological subtypes - sleep propensity and sleep fragmentation. Shared genetic links are also seen with obesity, coronary heart disease, psychiatric diseases, cognitive traits and reproductive ageing.
Hassan S Dashti - One of the best experts on this subject based on the ideXlab platform.
-
genome wide association analysis of self reported Daytime sleepiness identifies 42 loci that suggest biological subtypes
Nature Communications, 2019Co-Authors: Heming Wang, Jacqueline M Lane, Samuel E Jones, Hassan S Dashti, Hanna Ollila, Andrew R Wood, V Van HeesAbstract:Excessive Daytime sleepiness (EDS) affects 10–20% of the population and is associated with substantial functional deficits. Here, we identify 42 loci for self-reported Daytime sleepiness in GWAS of 452,071 individuals from the UK Biobank, with enrichment for genes expressed in brain tissues and in neuronal transmission pathways. We confirm the aggregate effect of a genetic risk score of 42 SNPs on Daytime sleepiness in independent Scandinavian cohorts and on other sleep disorders (restless legs syndrome, insomnia) and sleep traits (duration, chronotype, accelerometer-derived sleep efficiency and Daytime naps or inactivity). However, individual Daytime sleepiness signals vary in their associations with objective short vs long sleep, and with markers of sleep continuity. The 42 sleepiness variants primarily cluster into two predominant composite biological subtypes - sleep propensity and sleep fragmentation. Shared genetic links are also seen with obesity, coronary heart disease, psychiatric diseases, cognitive traits and reproductive ageing. A main symptom of chronic insufficient sleep is excessive Daytime sleepiness. Here, Wang et al. report 42 genome-wide significant loci for self-reported Daytime sleepiness in 452,071 individuals from the UK Biobank that cluster into two biological subtypes of either sleep propensity or sleep fragmentation.
-
genome wide association analysis of self reported Daytime sleepiness identifies 42 loci that suggest biological subtypes
Nature Communications, 2019Co-Authors: Heming Wang, Jacqueline M Lane, Samuel E Jones, Hassan S Dashti, Hanna Ollila, Andrew R Wood, Vincent T Van HeesAbstract:Excessive Daytime sleepiness (EDS) affects 10-20% of the population and is associated with substantial functional deficits. Here, we identify 42 loci for self-reported Daytime sleepiness in GWAS of 452,071 individuals from the UK Biobank, with enrichment for genes expressed in brain tissues and in neuronal transmission pathways. We confirm the aggregate effect of a genetic risk score of 42 SNPs on Daytime sleepiness in independent Scandinavian cohorts and on other sleep disorders (restless legs syndrome, insomnia) and sleep traits (duration, chronotype, accelerometer-derived sleep efficiency and Daytime naps or inactivity). However, individual Daytime sleepiness signals vary in their associations with objective short vs long sleep, and with markers of sleep continuity. The 42 sleepiness variants primarily cluster into two predominant composite biological subtypes - sleep propensity and sleep fragmentation. Shared genetic links are also seen with obesity, coronary heart disease, psychiatric diseases, cognitive traits and reproductive ageing.